AN OPEN‐LABEL, PHASE 1/2 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN + ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE IN PAEDIATRIC PATIENTS WITH ADVANCED STAGE HODGKIN LYMPHOMA